Research Article

Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis

Yuhui Li,1 Yimin Li,1 Jian Wu,2 Miao Miao,1 Xiaojuan Gao,3 Wenxin Cai,1 Miao Shao,1 Xuewu Zhang,1 Yan Xu,4 Lu Cong,4 Jing He,1 and Xiaolin Sun1

1Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism and Immune Diagnosis (BZ0135), Peking University People’s Hospital, Beijing, China
2Department of Nephrology, Beijing Daxing District People’s Hospital, Beijing, China
3Department of Rheumatology, Ningde Hospital, Affiliated Hospital of Fujian Medical University, Ningde, China
4Department of Neurology, People’s Hospital of Peking University, Beijing, China

Correspondence should be addressed to Jing He; hejing1105@126.com and Xiaolin Sun; sunxiaolin_sxl@126.com

Received 1 August 2020; Revised 10 November 2020; Accepted 16 November 2020; Published 25 November 2020

Academic Editor: Carlo Perricone

Objective. Antimelanoma differentiation-associated protein 5 (anti-MDA5) autoantibody has been reported in dermatomyositis (DM) to be associated with rapidly progressive interstitial lung disease (RP-ILD). Our study is aimed at determining the clinical characteristics and prognostic factors underpinning anti-MDA5-associated RP-ILD. Methods. Patients with anti-MDA5-associated DM (aMDA5-DM) were identified at the Peking University People’s Hospital. The presence of anti-MDA5 antibody was determined by immunoblotting. Kaplan-Meier, chi-square test, univariate, and multivariate data analyses were used. Results. Out of 213 patients with DM and clinically amyopathic dermatomyositis (CADM), 20.7% (44/213) of patients were identified as aMDA5-DM. Amongst the aMDA5-DM patients, 63.6% (28/44) were identified as having anti-MDA5-associated RP-ILD. During the follow-up, 32.1% (9/28) of patients with anti-MDA5-associated RP-ILD died of respiratory failure. We identified older age and periungual erythema as two independent risk factors for RP-ILD mortality. Age ≥57 years at disease onset was significantly associated with poor survival (P = 0.02) in patients with anti-MDA5-associated RP-ILD, while patients with periungual erythema had a better survival rate than those without periungual erythema (P < 0.05). Conclusions. Anti-MDA5-associated RP-ILD is significantly associated with poor survival rates in DM/CADM patients. More effective intervention should be administered to anti-MDA5-associated RP-ILD patients, especially to senior patients and those without periungual erythema.

1. Introduction

Dermatomyositis (DM) is a systemic autoimmune disease featuring a characteristic skin rash, proximal muscle weakness, and extramuscular manifestations such as interstitial lung disease (ILD), fever, and arthralgia. ILD is a predictive factor for poor DM/clinically amyopathic dermatomyositis (CADM) outcome [1, 2], and DM patients with rapidly progressive ILD (RP-ILD) are subject to a devastatingly high mortality rate [2, 3].

Myositis specific autoantibodies (MSAs), including anti-TIF-1y, anti-NXP2, anti-Mi-2, anti-MDA5, and anti-SAE, have been found to be associated with DM in the past decade [4]. Different autoantibodies are correlated with different clinical phenotypes. In DM, aMDA5-DM is a specific subtype that has been identified to be associated with RP-ILD [5]. Anti-MDA5 antibody was originally reported on 2005 by Sato et al. [6] in a study of Japanese patients with CADM and RP-ILD. Compared with other DM subtypes, the presence of aMDA5-DM was associated with a lower survival rate due to the high prevalence of RP-ILD [7]. Chen et al. [8] reported that 78.9% of patients with aMDA5-DM developed RP-ILD. Additionally, Chen et al. [9] demonstrated that 85.7% of patients with aMDA5-DM died of RP-ILD.
However, due to the heterogeneity of aMDA5-DM, the prevalence of RP-ILD and RP-ILD survival rates are variable [5, 10]. The predictive factors for poor outcome in aMDA5-DM patients with RP-ILD are not well-understood. In the present study, we compared the clinical and laboratory characteristics of patients with aMDA5-DM at the time when they were or were not diagnosed with RP-ILD. We identified initial predictive factors associated with mortality due to respiratory failure in a large anti-MDA5-associated RP-ILD cohort with DM in China.

2. Materials and Methods

2.1. Study Population. DM/CADM patient data were collected from clinical records of inpatients at the Department of Rheumatology and Immunology in Peking University People’s Hospital between July 2014 and October 2019. Patients were included based on a definite DM or CADM diagnosis in accordance with Bohan and Peter or Southener’s definitions [11, 12]. The study was approved by the ethics committee of Peking University People’s Hospital (2020PH114-01).

The following data from hospital records were gathered at the initial diagnosis of myositis: (1) demographics including age at onset, gender, and disease duration at diagnosis; (2) clinical data including Gottron’s sign/papules, skin ulceration, heliotrope rash, neck V-sign, shawl sign, mechanic’s hands, periangual erythema, subcutaneous calcinosis, myalgia in proximal limbs, and arthritis; (3) levels of serum muscle enzymes, including creatine kinase (CK, reference value 43-165 U/L), lactate dehydrogenase (LDH, 109-245 U/L), and ferritin (13-150 ng/mL); (4) myositis-specific autoantibodies (antigen including synthetase, NXP2, SAE, Mi-2, TIF-1γ, and MDA5), which were identified with immunoblotting according to manufacturers’ instructions (Euroimmun, Germany); (5) arterial blood gas analysis, including PaO₂ and PaCO₂; (6) pulmonary function tests (PFT) were reported when available, including forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), and total lung capacity (TLC); (7) measures from ILD chest images acquired with high-resolution computed tomography (HRCT), including ground-glass attenuation, consolidations, bronchovascular bundle thickening, and evidence of honeycombing or traction bronchiectasis; (8) measures from cytological analysis of bronchoalveolar lavage fluid if performed, including total cell number and ratios of macrophage and lymphocytes. The follow-up period was the duration from diagnosis of myositis to the last visit prior to October 2019 or death.

OM or CADM patients who were positive for anti-MDA5 were defined as aMDA5-DM in accordance with 2019 DM criteria [4]. aMDA5-DM patients were divided into two groups, those with and those without RP-ILD. The RP-ILD group was defined as rapidly progressive dyspnea directly due to ILD, requiring supplementary oxygen, hospitalization, or involving respiratory failure within three months of the ILD diagnosis. The non-RP-ILD group included patients with chronic ILD (C-ILD) and patients without ILD. Exclusion criteria included (1) patients who also had other autoimmune diseases including systemic lupus erythematosus, systemic sclerosis, and rheumatoid arthritis; (2) patients with lung cancer and chronic pulmonary disease including occupational-environmental exposures and chronic obstructive pulmonary disease; (3) patients receiving treatment involving systemic glucocorticoid and immunosuppressant agents before coming to the hospital.

2.2. Statistical Analysis. Continuous variables are reported as the mean ± standard deviation, and categorical variables are reported as both count and percentage. Group comparisons between anti-MDA5-associate RP-ILD and non-RP-ILD patients were assessed with Student’s t-tests or Mann-Whitney U tests. Patient outcomes were compared between the anti-MDA5-associate RP-ILD and MDA5-positive non-RP-ILD groups. Survival rate between groups was compared using the Kaplan-Meier curve with the log-rank test. Cox proportional hazards model was used for comparing pulmonary outcomes and survival. First, univariate analysis was done by Cox proportional hazards model, then, the P value less than 0.05 and PaO₂ less than 60 mmHg which means respiratory failure were included in the multivariate analysis by Cox proportional hazards model while forward selection was used in SPSS 23.0.

3. Results

3.1. Clinical and Laboratory Characteristics of Anti-MDA5-Associated DM. Anti-MDA5 antibody was positive in 20.7% (44/213) of patients with DM/CADM (Table 1). The prevalence of anti-MDA5 antibody in DM and CADM was 7.6% (10/132) and 42% (34/81), respectively. Heliotrope rash, shawl sign, periangual erythema, and skin ulceration were observed to be significantly more common in anti-MDA5-positive patients compared with anti-MDA5-negative patients, with incidence rates of 68.2% vs. 43.2%, 56.8% vs. 27.2%, 29.5% vs. 16.0%, and 38.6% vs. 5.9%, respectively (all \( P < 0.05 \)). On the other hand, the levels of CK (\( P = 0.001 \)) and LDH (\( P = 0.011 \)) were found to be significantly lower in anti-MDA5-positive patients than in anti-MDA5-negative subjects. The prevalence of antianinoacyl-tRNA synthetase (ARS) antibodies was also significantly lower in anti-MDA5-positive subjects (\( P = 0.001 \)). Anti-MDA5 antibody was significantly associated with RP-ILD, as RP-ILD developed in 63.6% (28/44) of anti-MDA5-positive patients compared with 29.0% (49/169) of anti-MDA5-negative patients (\( P < 0.001 \)). The incidence of death due to ILD in anti-MDA5-positive patients was 20.5% (9/44), significantly higher than that of the anti-MDA5-negative group (4.7%, 8/169) (\( P = 0.002 \)).

3.2. Clinical and Laboratory Manifestations of aMDA5-DM Patients with RP-ILD. Out of the 44 patients with aMDA5-DM, 28 had RP-ILD, 8 had C-ILD, and 8 did not have ILD. We compared the clinical and laboratory features between these 3 groups (Table 2). Those with RP-ILD were older (56.0 ± 9.1 years) than those with C-ILD (38.7 ± 13.8 years, \( P < 0.001 \)). There was no significant difference in duration
from disease onset to diagnosis, incidence of Gottron’s sign/papules, mechanic’s hands, heliotrope rash, or skin ulceration between the groups. Moreover, while serum ferritin was higher in patients with RP-ILD compared with those without RP-ILD, there was no significant difference between groups. PaO₂ was significantly lower in the RP-ILD group than in the C-ILD group (77.02 ± 16.79 vs. 91.65 ± 12.51 mmHg, P = 0.042). PFTs variables were significantly decreased in patients with RP-ILD compared with those with C-ILD, including DLCO (60 ± 15.6 vs. 78.2 ± 10.8% predicted, P = 0.019) and TLC (80.2 ± 10.5 vs. 100.4 ± 12.6% predicted, P = 0.001). Chest HRCT images were available for all patients with ILD. These images revealed a number of features that were more common for patients with RP-ILD compared with those with C-ILD, including ground-glass attenuation (92.9% vs. 37.5%, P = 0.003), consolidation (64.3% vs. 12.5%, P = 0.016), and bronchovascular bundle thickening (89.3% vs. 50.0%, P = 0.030). Analysis of cell composition in BALF demonstrated that patients with RP-ILD had significantly decreased numbers of macrophages compared with patients with C-ILD (42.4 ± 20.1% vs. 61.6 ± 19.0%, P = 0.018). The mortality rate due to ILD in patients with RP-ILD was 32.1% (9/28), which was higher than that for patients with C-ILD (0%) or without ILD (0%).

### 3.3. Comparison of Clinical and Laboratory Characteristics between Survived and Nonsurvived Patients with Anti-MDA5-Associated RP-ILD

We divided patients with anti-MDA5-associated RP-ILD into survived and nonsurvived groups (Table 3). Age at disease onset of nonsurvived patients was older than survived patients (62.8 ± 6.2 vs. 53.6 ± 9.2 years, P = 0.012). Additionally, the number of peripheral blood lymphocytes was lower in nonsurvived patients compared with survived patients, with average numbers of 0.5 × 10⁵/L and 1.0 × 10⁵/L (P = 0.012), respectively. Although serum level of CRP and ferritin were higher in the nonsurvived group than in the survived group, this difference did not reach statistical significance. Likewise, there was no significant difference between the groups in incidences of Gottron’s sign/papules, mechanic’s hands, heliotrope rash, or skin ulceration between the groups.

| Variable | DM/CADM (n = 213) | Anti-MDA5-positive group (n = 44) | Anti-MDA5-negative group (n = 169) | P value |
|----------|------------------|----------------------------------|----------------------------------|---------|
| Age at onset, years | 52.38 ± 12.99 | 51.76 ± 14.66 | 0.800 |
| DM, no. (%) | 10/132 (7.6) | 122/132 (92.4) | <0.001 |
| CADM, no. (%) | 34/81 (42.0) | 47/81 (58.0) | <0.001 |
| Female, no. (%) | 31 (70.5) | 126 (74.6) | 0.582 |
| Fever, no. (%) | 17 (38.6) | 59 (34.9) | 0.646 |
| Gottron’s sign/papules, no. (%) | 38 (86.4) | 129 (76.3) | 0.150 |
| Mechanic’s hands, no. (%) | 23 (52.3) | 73 (43.2) | 0.281 |
| Heliotrope rash, no. (%) | 30 (68.2) | 73 (43.2) | 0.003 |
| V sign, no. (%) | 25 (56.8) | 77 (45.6) | 0.183 |
| Shawl sign, no. (%) | 25 (56.8) | 46 (27.2) | <0.001 |
| Subcutaneous calcinosis, no. (%) | 0 (0) | 7 (4.1) | 0.369 |
| Periungual erythema, no. (%) | 13 (29.5) | 27 (16.0) | 0.040 |
| Skin ulceration, no. (%) | 17 (38.6) | 10 (5.9) | <0.001 |
| Arthritis, no. (%) | 24 (54.5) | 69 (40.8) | 0.102 |
| Myalgia, no. (%) | 22 (50.0) | 76 (45.0) | 0.551 |
| CK, U/L | 208.7 ± 559.27 | 674.49 ± 1327.58 | 0.001 |
| LDH, U/L | 510.56 ± 103.41 | 374.73 ± 251.14 | 0.011 |
| CRP level, mg/L | 10.59 ± 19.3 | 13.82 ± 23.39 | 0.400 |
| Anti-SAE antibody, no. (%) | 0 (0) | 6 (3.6) | 0.349 |
| Anti-Mi-2 antibody, no. (%) | 1 (2.3) | 8 (4.7) | 0.763 |
| Anti-TIF-1γ antibody, no. (%) | 3 (6.8) | 7 (4.1) | 0.728 |
| Anti-NXP2 antibody, no. (%) | 2 (4.5) | 8 (4.7) | 1.000 |
| Anti-ARS antibodies, no. (%) | 5 (11.4) | 63 (37.3) | 0.001 |
| ILD, no. (%) | 36 (81.8) | 128 (75.7) | 0.393 |
| RP-ILD, no. (%) | 28 (63.6) | 49 (29.0) | <0.001 |
| Mortality, no. (%) | 9 (20.5) | 8 (4.7) | 0.002 |

Categorical data are presented as n (percent) of the patients. Continuous data are presented as mean ± standard deviation. DM: dermatomyositis; CADM: clinically amyopathic dermatomyositis; MDA5: melanoma differentiation-associated gene 5; CK: creatine kinase; LDH: lactate dehydrogenase; CRP: C-reactive protein; SAE: small ubiquitin-like modifier enzyme; TIF-1γ: translation initiation factor-1γ; NXP2: nuclear matrix protein 2; ARS: aminoacyl-tRNA synthetase; ILD: interstitial lung disease.
Table 2: Comparison of clinical and laboratory characteristics between the RP-ILD and non-RP-ILD groups in anti-MDA5-positive DM patients.

| Variables                      | RP-ILD (n = 28) | aMDA5-DM (n = 44) | C-ILD (n = 8) | Non-ILD (n = 8) | P value RP vs. C-ILD | P value RP vs. non-ILD |
|--------------------------------|----------------|------------------|--------------|----------------|----------------------|-----------------------|
| Age at diagnosis, years        | 56.0 ± 9.1     | 38.7 ± 13.8      | 49.4 ± 15.3  | <0.001         | 0.151                |
| Duration from disease onset to diagnosis, months | 5.0 ± 6.3     | 24.8 ± 58.0      | 5.3 ± 4.6    | 0.055          | 0.979                |
| Female, no. (%)                | 22 (78.6)      | 5 (62.5)         | 4 (50)       | 0.253          | 0.643                |
| Fever, no. (%)                 | 11 (39.2)      | 2 (25)           | 4 (50)       | 0.892          | 0.746                |
| Gottron’s sign/papules, no. (%)| 26 (92.9)      | 6 (75)           | 6 (75)       | 0.436          | 0.436                |
| Mechanic’s hands, no. (%)      | 14 (50)        | 3 (37.5)         | 6 (75)       | 0.394          | 0.823                |
| Heliotrope rash, no. (%)       | 19 (67.9)      | 6 (75)           | 5 (62.5)     | 1.000          | 1.000                |
| Skin ulceration, no. (%)       | 13 (46.4)      | 1 (12.5)         | 3 (37.5)     | 0.964          | 0.185                |
| Periungual erythema, no. (%)   | 10 (35.7)      | 2 (25)           | 1 (12.5)     | 0.411          | 0.887                |
| Myalgia, no. (%)               | 17 (60.7)      | 3 (37.5)         | 2 (25)       | 0.167          | 0.446                |
| Alopecia, no. (%)              | 7 (25)         | 5 (62.5)         | 5 (62.5)     | 0.119          | 0.119                |
| Lymphocytes count, ×10⁹/L       | 0.9 ± 0.5      | 1.2 ± 0.5        | 1.3 ± 0.7    | 0.081          | 0.196                |
| CK, U/L                        | 276.0 ± 691.9  | 127 ± 147.1      | 53.9 ± 22.5  | 0.517          | 0.332                |
| Ferritin (ng/mL)               | 1417.3 ± 1113.8| 54.4 ± 65.5      | 34.1         | 0.612          | 0.142                |
| CRP level, mg/L                | 13.3 ± 22.9    | 9.16 ± 12.1      | 2.7 ± 3.3    | 0.179          | 0.598                |
| Arterial blood gas analysisb   |               |                  |              |                |                      |
| PaO₂, mmHg                     | 77.0 ± 16.8    | 91.7 ± 12.5      | -            | 0.042          | -                    |
| PFT (% predicted)c             |               |                  |              |                |                      |
| FVC                            | 79.5 ± 17.1    | 97.3 ± 17.6      | -            | 0.072          | -                    |
| DLco                           | 60 ± 15.6      | 78.2 ± 10.8      | -            | 0.019          | -                    |
| TLC                            | 80.2 ± 10.5    | 100.4 ± 12.6     | -            | 0.001          | -                    |
| HRCT                           |               |                  |              |                |                      |
| Ground-glass attenuation       | 26 (92.9)      | 3 (37.5)         | -            | 0.003          | -                    |
| Consolidation                  | 18 (64.3)      | 1 (12.5)         | -            | 0.016          | -                    |
| Traction bronchiectasis        | 9 (32.1)       | 0 (0.0)          | -            | 0.160          | -                    |
| Bronchovascular bundle thickening | 25 (89.3) | 4 (50.0)         | -            | 0.030          | -                    |
| Bronchoalveolar lavaged        |               |                  |              |                |                      |
| Total cell number (×10⁵/mL)     | 0.43 ± 0.50    | 0.47 ± 0.57      | -            | 0.742          | -                    |
| Macrophage (%)                 | 42.4 ± 20.1    | 61.6 ± 19.0      | -            | 0.018          | -                    |
| Lymphocyte (%)                 | 49.3 ± 22.9    | 37.3 ± 19.0      | -            |               |                      |
| Mortality, no. (%)             | 9 (32.1)       | 0 (0)            | 0 (0)        | 0.076          | 0.076                |

Continuous data are expressed as mean ± standard deviation. 8 patients of 28, 20 values missing in RP-ILD group and 7 values missing in the non-ILD group. 14 patients of 44, 30 values missing in the RP-ILD group. 22 patients of 44, 22 values missing in the RP-ILD group. RP-ILD: rapidly progressive interstitial lung disease; MDA5: melanoma differentiation-associated gene 5; DM: dermatomyositis; RF: respiratory failure; CK: creatine kinase; LDH: lactate dehydrogenase; PFT: pulmonary function test; FVC: forced vital capacity; DLCO: diffusion capacity for carbon monoxide; TLC: total lung capacity.

Figure 1. Results of a survival analysis in the anti-MDA5-associated RP-ILD group are presented in Table 4. Poor prognosis for these patients was associated with an age at onset of ≥57 years, having lymphocytes in peripheral blood of less than 0.7 × 10⁹/L and having CRP ≥28.9 mg/L. Cox multivariate regression analysis revealed that age at onset ≥57 years (HR 18.54, 95% CI 1.51-227.94, and P = 0.023) and having periungual erythema (HR 0.08, 95% CI 0.01-0.96, and P = 0.046) were independent predictors of mortality due to RP-ILD. The significant predictors from univariate and multivariate survival analyses were then entered into a
Kaplan-Meier analysis with log rank (Figure 2). Results indicated that patients whose age was ≥ 57 years at disease onset had a survival rate of 39% after 1 year and 29.2% after 3 years, while patients who were less than 57 years old at disease onset showed a significantly higher survival rate (92.3% after both 1 and 3 years; P = 0.02; Figure 2(a)). Further, patients with periungual erythema at disease onset had better survival (87.5% after both 1 and 3 years) than patients without periungual erythema (54.5% at 1 year and 43.6% at 3 years; P = 0.098) (Figure 2(b)). Patients with more peripheral blood lymphocytes (≥ 0.7 × 10^9/L) had better survival than those with fewer lymphocytes (< 0.7 × 10^9/L) (P = 0.012) (Figure 2(c)). Higher CRP (≥ 28.9 mg/L) was significantly associated with poorer survival than patients with lower CRP (< 28.9 mg/L) (P = 0.002) (Figure 2(d)).

4. Discussion

In terms of mortality, aMDA5-DM has been identified as a more severe DM subtype than other types of myositis [13, 14]. As a common complication of aMDA5-DM, RP-ILD has been found to be the most important cause of poor survival of this DM subtype [5, 10]. In the current study, we identified initial predictors for the survival of
anti-MDA5-associated DM patients with RP-ILD in a patient cohort from China.

The prevalence of anti-MDA5 antibody in our DM/CADM patients was 20.7%, which is consistent with other studies from China (15–20%), but higher than that of patients from Europe and North American (4–7%) [15–17]. Rates of cutaneous manifestations, including ulceration and periungual erythema, observed in patients with anti-MDA5-associated DM were similar to those described previously [18]. Shawl sign was newly revealed to be associated with anti-MDA5-associated DM in this study. The association between heliotrope rash and the MDA5 antibody has been mixed in previous studies. A small-scale retrospective study that included 10 patients with anti-MDA5 by Fiorentino et al. [18] reported that heliotrope rash was not associated with the MDA5 antibody. In contrast, a study on PM/DM patients from Europe reported that heliotrope rash was associated with the MDA5 antibody [15]. Our study revealed a strong association between heliotrope rash and the anti-MDA5 antibody. Relatively low CK and LDH levels observed in our study are consistent with the previous studies [13, 14]. In our cohort, 63.6% of patients with anti-MDA5-associated myositis had RP-ILD, which is consistent with other studies that aMDA5-DM is associated with a high incidence of RP-ILD.

Our results confirmed, in an independent and large Chinese DM/CADM patient cohort, several factors associated with RP-ILD in previous studies, including age at disease onset, decreased lymphocytes in peripheral blood, PaO₂ levels, baseline DLco and TLC, and evidence of ground-glass attenuation or consolidation in HRCT [10, 19–22]. The association between high baseline concentration of serum ferritin and anti-MDA5-associated RP-ILD has been previously reported [10]; while we found that serum ferritin was higher for patients with RP-ILD, the group difference was not statistically significant, possibly because only a few patients received ferritin tests, leading to insufficient statistical power. Alopecia was reported to be associated with anti-MDA5 antibody in patients with myositis [20]. However, the reverse association between alopecia and anti-MDA5-associated RP-ILD was first revealed in this study. This result suggests that the presence of alopecia might be a protective factor against the development of RP-ILD. The prognostic value of periungual erythema in patients with aMDA5-DM has not been well-examined in previous studies, although a recent study from Japan [22] indicated that periungual...
erythema is associated with mortality due to ILD. In contrast, another study from Brazil [23] reported that periungual hyperemia was found more common in myositis patients without MDA5 antibody. Our study found that periungual erythema is a protective predictor for anti-MDA5-associated RP-ILD survival and suggest that aMDA5-DM patients with periungual erythema might have better survival.

Mortality due to respiratory failure was observed in 32.1% of aMDA5-DM patients with RP-ILD but not in patients without RP-ILD. Although patients with anti-MDA5 had poorer outcomes, this finding indicated that, in terms of aMDA5-DM, one-third of those patients without RP-ILD still had better survival.

There are several limitations in this study. First, selection bias cannot be ruled out because clinical records were collected from a single center in this retrospective study, and high prevalence of positive aMDA5-DM cannot be avoided since the patients with anti-MDA5 antibody were more likely admitted to hospital. Second, statistical bias cannot be avoided because laboratory tests such as ferritin, CRP, or arterial blood gas analysis were not performed in some patients due to its retrospective design. Therefore, larger population-based multicenter studies are required in the future for more accurate information.

5. Conclusions

In conclusion, anti-MDA5-associated RP-ILD is significantly associated with poor outcome in DM patients. Anti-MDA5-associated RP-ILD patients, especially more senior patients and those without periungual erythema, should receive more intensive treatment.

Data Availability

The data that support the findings of this study are available upon request.

Conflicts of Interest

The authors have declared that they have no competing interests.

Authors’ Contributions

Yuhui Li, Yimin Li, and Jian Wu contributed equally to this work.

Acknowledgments

The authors appreciate the assistance of Daojun Hong and Jun Zhang in the verification of muscular pathology. This work was supported by the National Natural Science Foundation of China (81801617, 81671602, and 31870879), Beijing Sci-Tech grant (Z19110000619114), Peking University People’s Hospital Research and Development Foundation (RDY2018-01, RS2018-02, RDKP2019-02, RDE2019-02, and RDX2019-03), and the Clinical Medicine Plus X-Young Scholars Project of Peking University Research Funds for Central Universities.

References

[1] B. Hervier and Y. Uzunhan, “Inflammatory myopathy-related interstitial lung disease: from pathophysiology to treatment,” Frontiers in Medicine, vol. 6, p. 326, 2020.
[2] R. Jablonski, S. Bhorade, M. E. Strek, and J. Dematte, “Recognition and management of myositis-associated rapidly progressive interstitial lung disease,” Chest, vol. 158, no. 1, pp. 252–263, 2020.
[3] J. Morisset, C. Johnson, E. Rich, H. R. Collard, and J. S. Lee, “Management of myositis-related interstitial lung disease,” Chest, vol. 150, no. 5, pp. 1118–1128, 2016.
[4] A. L. Mamman, Y. Allenbach, W. Stenzel et al., “239th ENMC International Workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018,” Neuro muscular Disorders, vol. 30, no. 1, pp. 70–92, 2020.
[5] S. Moghadam-Kia, C. V. Oddis, S. Sato, M. Kuwana, and R. Aggarwal, “Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis,” Arthritis Care & Research, vol. 68, no. 5, pp. 689–694, 2016.
[6] S. Sato, M. Hirakata, M. Kuwana et al., “Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis,” Arthritis and Rheumatism, vol. 52, no. 5, pp. 1571–1576, 2005.
[7] M. P. Debray, R. Borie, M. P. Revel et al., “Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings,” European Journal of Radiology, vol. 84, no. 3, pp. 516–523, 2015.
[8] F. Chen, D. Wang, X. Shu, R. Nakashima, and G. Wang, “Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis,” Rheumatology International, vol. 32, no. 12, pp. 3909–3915, 2012.
[9] Z. Chen, M. Cao, M. N. Plana et al., “Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis,” Arthritis Care & Research, vol. 65, no. 8, pp. 1316–1324, 2013.
[10] T. Gono, Y. Kawaguchi, T. Satoh et al., “Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis,” Rheumatology (Oxford), vol. 49, no. 9, pp. 1713–1719, 2010.
[11] A. Bohan and J. B. Peter, “Polymyositis and dermatomyositis (first of two parts),” The New England Journal of Medicine, vol. 292, no. 7, pp. 344–347, 1975.
[12] R. D. Sontheimer, “Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?,” Journal of the American Academy of Dermatology, vol. 46, no. 4, pp. 626–636, 2002.
[13] T. Koga, K. Fujikawa, Y. Horai et al., “The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with
[14] Y. Abe, M. Matsushita, K. Tada, K. Yamaji, Y. Takasaki, and N. Tamura, “Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis,” *Rheumatology (Oxford)*, vol. 56, no. 9, pp. 1492–1497, 2017.

[15] A. Ceribelli, M. Fredi, M. Taraborelli et al., “Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis,” *Clinical and Experimental Rheumatology*, vol. 32, no. 6, pp. 891–897, 2014.

[16] Y. Kochi, Y. Kamatani, Y. Kondo et al., “Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis,” *Annals of the Rheumatic Diseases*, vol. 77, no. 4, pp. 602–611, 2018.

[17] S. Moghadam-Kia, C. V. Oddis, S. Sato, M. Kuwana, and R. Aggarwal, ”Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical Spectrum in North American patients with dermatomyositis,” *The Journal of Rheumatology*, vol. 44, no. 3, pp. 319–325, 2017.

[18] D. Fiorentino, L. Chung, J. Zwerner, A. Rosen, and L. Casciola-Rosen, “The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study,” *Journal of the American Academy of Dermatology*, vol. 65, no. 1, pp. 25–34, 2011.

[19] K. Tanizawa, T. Handa, R. Nakashima et al., “The prognostic value of HRCT in myositis-associated interstitial lung disease,” *Respiratory Medicine*, vol. 107, no. 5, pp. 745–752, 2013.

[20] J. Li, Y. Liu, Y. Li et al., ”Associations between anti-melanoma differentiation-associated gene 5 antibody and demographics, clinical characteristics and laboratory results of patients with dermatomyositis: a systematic meta-analysis,” *The Journal of Dermatology*, vol. 45, no. 1, pp. 46–52, 2018.

[21] K. Yamaguchi, A. Yamaguchi, Y. Onuki et al., ”Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age,” *Modern Rheumatology*, pp. 1–9, 2020.

[22] S. Sato, K. Masui, N. Nishina et al., “Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients,” *Rheumatology*, vol. 57, no. 7, pp. 1212–1221, 2018.

[23] I. B. P. Borges, M. G. Silva, and S. K. Shinjo, ”Prevalence and reactivity of anti-melanoma differentiation-associated gene 5 (anti-MDA-5) autoantibody in Brazilian patients with dermatomyositis,” *Anais Brasileiros de Dermatologia*, vol. 93, no. 4, pp. 517–523, 2018.